查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2023541

腮腺炎疫苗市場分析與預測（至2035年）：應用、疫苗類型、給藥途徑及通路

Mumps Vaccine Market Analysis and Forecast to 2035: Application, Vaccine Type, Route of Administration, Distribution Channel
出版日期: | 出版商: Global Insight Services | 英文 350 Pages | 商品交期: 3-5個工作天內

價格
簡介目錄

全球流行性腮腺炎疫苗市場預計將從2025年的28億美元成長到2035年的52億美元，複合年成長率（CAGR）為6.1%。推動腮腺炎疫苗市場成長的因素包括免疫接種資金的增加和穩定的人口需求。各國政府正透過美國疾病管制與預防中心（CDC）主導的計畫擴大疫苗採購，而美國每年約360萬的穩定新生兒群體也支撐著基本需求。加強疫情監測正在推動加強免疫接種宣傳活動，尤其是在人口稠密地區。此外，世界衛生組織（WHO）報告的全球麻疹疫情反彈也提高了麻疹、腮腺炎和德國麻疹（MMR）疫苗的接種率。加強對學校免疫接種的監管力度以及低溫運輸基礎設施的改善，進一步確保了疫苗供應穩定、減少浪費並提高了全部區域疫苗接種率。

在全球流行性腮腺炎疫苗市場，根據抗原組成，疫苗類型可分為單價疫苗、三價疫苗和四價疫苗。三價和四價疫苗佔據市場主導地位，因為它們只需接種一劑即可預防多種疾病，從而提高免疫效率和疫苗接種率。預計到2025年，三價和單價疫苗的市場規模將達到約15.15億美元。麻疹、腮腺炎、德國麻疹合併疫苗（MMR）和麻疹、腮腺炎、德國麻疹、水痘合併疫苗（MMRV）等聯合疫苗已被廣泛應用於各國免疫規劃中，以減少注射次數並提高疫苗接種依從性。在全球範圍內，對多價疫苗的需求持續成長，這主要得益於對兒童疫苗接種和公共衛生工作的日益重視。

市場區隔
目的 兒童、成人
疫苗種類 四價、三價、一價
給藥途徑 皮下注射、肌肉注射
銷售管道 醫院、診所、疫苗接種中心和公共衛生診所等

在全球流行性腮腺炎疫苗市場中，給藥途徑分為皮下注射和肌肉注射。皮下注射佔主導地位，因為它廣泛用於麻疹、腮腺炎、德國麻疹等活病毒疫苗的接種，預計到2025年市場規模將達到約20.323億美元。這種方法可以控制抗原吸收，並被廣泛應用於全球兒童常規免疫接種計劃。肌肉注射也因其高效的免疫反應和標準化的給藥流程而在臨床和醫院中廣泛應用。全球疫苗接種率的提高和對免疫接種指南的遵循程度的提高，推動了對這兩種給藥途徑的需求，以確保有效預防疾病。

區域概覽

預計2025年，北美將引領全球流行性腮腺炎疫苗市場，約佔總銷售額的39.0%。這一成長主要得益於美國和加拿大反覆爆發的腮腺炎疫情以及強力的公共衛生應對措施。為因應病例報告的增加和疫苗豁免率的上升，各國政府正在加強免疫接種計劃和宣傳宣傳活動。同時，民眾對兒童疫苗的高度信任以及學校的免疫接種要求也支撐了穩定的疫苗接種率。這些因素共同確保了疫苗需求的穩定，並鞏固了北美在全球市場的主導地位。

預計2026年至2035年，亞太地區腮腺炎疫苗市場將以7.9%的複合年成長率成長，成為成長最快的地區。這一成長主要受印尼、新加坡和紐西蘭等國麻疹和流行性腮腺炎疫情的不斷蔓延所驅動，從而推高了對麻疹、腮腺炎、德國麻疹聯合疫苗（MMR疫苗）的需求。政府強制推行的免疫接種計畫以及免費或津貼疫苗的普及，使得疫苗接種率不斷提高。此外，針對疫情的積極應對宣傳活動以及群體免疫意識的增強，也加速了疫苗的分發，使亞太地區成為重要的成長區域。

主要趨勢和促進因素

腮腺炎疫苗市場轉向聯合疫苗的轉變：

在腮腺炎疫苗市場，聯合疫苗和先進的給藥技術正被廣泛採用，以提高疫苗接種率並簡化給藥流程。麻疹、腮腺炎、德國麻疹 (MMR) 和麻疹、腮腺炎、德國麻疹、水痘 (MMRV) 等疫苗已被廣泛應用，只需接種一劑即可預防多種疾病，從而提高疫苗接種依從性並降低物流複雜性。在世界衛生組織 (WHO) 和聯合國兒童基金會 (UNICEF) 等機構的支持下，諸如微陣列貼片、鼻噴劑和噴射注射器等可實現無針給藥的創新技術正在湧現。這些進步正在提高疫苗的可及性，減少對低溫運輸的依賴，並加強全球免疫接種效果，尤其是在資源匱乏的環境中。

政府大規模宣傳活動和國際資金投入腮腺炎疫苗市場：

腮腺炎疫苗市場主要受各國政府大規模免疫規劃和全球衛生組織資金的驅動。世界衛生組織（世衛組織）和聯合國兒童基金會等機構的聯合舉措正在推動廣泛覆蓋全球數百萬兒童的免疫宣傳活動。這些努力動員了醫護人員，提高了公眾意識，並加強了常規免疫接種系統。此外，美國等地區腮腺炎疫情的增加凸顯了確保持續免疫接種率的必要性。這些努力凸顯了公共衛生投資在擴大疫苗接種範圍和改善全球疾病預防方面的關鍵作用。

目錄

第1章執行摘要

第2章 市場亮點

第3章 市場動態

  • 宏觀經濟分析
  • 市場趨勢
  • 市場促進因素
  • 市場機遇
  • 市場限制因素
  • 複合年均成長率：成長分析
  • 影響分析
  • 新興市場
  • 技術藍圖
  • 戰略框架

第4章：細分市場分析

  • 市場規模及預測：依疫苗類型分類
    • 四價
    • 三價
    • 單價
  • 市場規模及預測：依給藥途徑分類
    • 皮下注射
    • 肌肉內注射
  • 市場規模及預測：依分銷通路分類
    • 醫院和診所
    • 疫苗接種中心和公共衛生診所
    • 其他
  • 市場規模及預測：依應用領域分類
    • 兒童
    • 成人

第5章 區域分析

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 其他拉丁美洲地區
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 韓國
    • 亞太其他地區
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 其他歐洲地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非
    • 其他中東和非洲地區

第6章 市場策略

  • 供需差距分析
  • 貿易和物流限制
  • 價格、成本和利潤率趨勢
  • 市場滲透率
  • 消費者分析
  • 監管概述

第7章 競爭訊息

  • 市場定位
  • 市場占有率
  • 競爭基準
  • 主要企業的策略

第8章：公司簡介

  • Sanofi SA
  • GSK plc
  • Sinovac Biotech Ltd
  • Serum Institute of India Pvt. Ltd
  • Zydus Group
  • Takeda Pharmaceutical Company Limited
  • Biological E Limited
  • Shanghai Institute of Biological Products Co., Ltd
  • Daiichi Sankyo Co., Ltd.
  • Merck & Co., Inc.

第9章 關於我們

簡介目錄
Product Code: GIS24643

The global mumps vaccine market is projected to grow from $2.8 billion in 2025 to $5.2 billion by 2035, at a compound annual growth rate (CAGR) of 6.1%. The mumps vaccine market is supported by rising immunization funding and stable demographic demand. Governments are expanding vaccine procurement through programs led by the Centers for Disease Control and Prevention, while consistent birth cohorts of around 3.6 million annually in the U.S. sustain baseline demand. Increasing outbreak surveillance is driving booster campaigns, particularly in high-density settings. Additionally, global measles resurgence reported by the World Health Organization is boosting uptake of MMR vaccines. Strengthened regulatory enforcement for school-entry immunization and improved cold-chain infrastructure are further ensuring stable supply, reduced wastage, and broader vaccine coverage across regions.

In the global mumps vaccine market, the vaccine type segment is categorized into monovalent, trivalent, and tetravalent vaccines based on antigen composition. Trivalent and tetravalent vaccines dominate due to their ability to provide protection against multiple diseases in a single dose, improving immunization efficiency and coverage. The trivalent and monovalent category accounted for about $1,515.0 million in 2025. Combination vaccines such as MMR and MMRV are widely adopted in national immunization programs to reduce the number of injections and enhance compliance. Growing emphasis on pediatric vaccination and public health initiatives continues to support demand for multivalent vaccines globally.

Market Segmentation
ApplicationPaediatrics, Adults
Vaccine TypeTetravalent, Trivalent and Monovalent
Route of AdministrationSubcutaneous, Intramuscular
Distribution ChannelHospitals & Clinics, Vaccine Centers and Public Health Clinics, Others

In the global mumps vaccine market, the route of administration segment includes subcutaneous and intramuscular methods. Subcutaneous administration dominates the segment due to its widespread use in delivering live attenuated vaccines such as MMR, reaching approximately $2,032.3 million in 2025. This method allows controlled antigen absorption and is commonly used in routine childhood immunization schedules worldwide. Intramuscular administration is also widely utilized in clinical and hospital settings for efficient immune response and standardized delivery practices. Increasing global vaccination coverage and adherence to immunization guidelines are driving demand for both administration routes to ensure effective disease prevention.

Geographical Overview

North America leads the global mumps vaccine market in 2025, accounting for approximately 39.0% of total revenue share. Growth is driven by recurring mumps outbreaks and strong public health responses in the United States and Canada. Increasing case reports and rising vaccine exemption rates are prompting authorities to strengthen immunization programs and awareness campaigns. At the same time, high public confidence in childhood vaccines and school immunization requirements support consistent uptake. These factors collectively ensure stable demand and reinforce North America's dominant position in the global market.

The Asia-Pacific region is projected to be the fastest-growing mumps vaccine market, registering a CAGR of 7.9% from 2026 to 2035. Growth is fueled by increasing measles and mumps outbreaks across countries such as Indonesia, Singapore, and New Zealand, which are driving demand for MMR vaccines. Government-mandated immunization programs and expanded access to free or subsidized vaccines are improving coverage rates. Additionally, proactive outbreak response campaigns and rising awareness of herd immunity are accelerating vaccine adoption, positioning Asia-Pacific as a key high-growth region.

Key Trends and Drivers

Shift Toward Combination Vaccine in the Mumps Vaccine Market:

The Mumps Vaccine Market is increasingly shifting toward combination vaccines and advanced delivery technologies to improve immunization coverage and simplify administration. Vaccines such as the MMR and MMRV formulations are widely adopted, offering protection against multiple diseases in a single dose, thereby enhancing compliance and reducing logistical complexity. Supported by organizations like World Health Organization and UNICEF, innovations such as microarray patches, intranasal sprays, and jet injectors are emerging to enable needle-free delivery. These advancements improve accessibility, reduce cold-chain dependency, and strengthen global vaccination outcomes, particularly in low-resource settings.

Large-Scale Government Campaigns and Global Funding Support in the Mumps Vaccine Market:

The Mumps Vaccine Market is significantly driven by large-scale government immunization programs and funding support from global health organizations. Collaborative initiatives involving entities such as World Health Organization and UNICEF have enabled widespread vaccination campaigns targeting millions of children worldwide. These efforts mobilize healthcare workers, enhance public awareness, and strengthen routine immunization systems. Additionally, rising incidences of mumps outbreaks in regions like the United States reinforce the need for sustained vaccination coverage. Such initiatives highlight the critical role of public health investment in expanding vaccine access and improving disease prevention globally.

Research Scope

  • Estimates and forecasts the overall market size across type, application, and region.
  • Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
  • Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
  • Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
  • Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
  • Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
  • Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

  • 1.1 Market Size and Forecast
  • 1.2 Market Overview
  • 1.3 Market Snapshot
  • 1.4 Regional Snapshot
  • 1.5 Strategic Recommendations
  • 1.6 Analyst Notes

2 Market Highlights

  • 2.1 Key Market Highlights by Vaccine Type
  • 2.2 Key Market Highlights by Route of Administration
  • 2.3 Key Market Highlights by Distribution Channel
  • 2.4 Key Market Highlights by Application

3 Market Dynamics

  • 3.1 Macroeconomic Analysis
  • 3.2 Market Trends
  • 3.3 Market Drivers
  • 3.4 Market Opportunities
  • 3.5 Market Restraints
  • 3.6 CAGR Growth Analysis
  • 3.7 Impact Analysis
  • 3.8 Emerging Markets
  • 3.9 Technology Roadmap
  • 3.10 Strategic Frameworks
    • 3.10.1 PORTER's 5 Forces Model
    • 3.10.2 ANSOFF Matrix
    • 3.10.3 4P's Model
    • 3.10.4 PESTLE Analysis

4 Segment Analysis

  • 4.1 Market Size & Forecast by Vaccine Type (2020-2035)
    • 4.1.1 Tetravalent
    • 4.1.2 Trivalent
    • 4.1.3 Monovalent
  • 4.2 Market Size & Forecast by Route of Administration (2020-2035)
    • 4.2.1 Subcutaneous
    • 4.2.2 Intramuscular
  • 4.3 Market Size & Forecast by Distribution Channel (2020-2035)
    • 4.3.1 Hospitals & Clinics
    • 4.3.2 Vaccine Centers and Public Health Clinics
    • 4.3.3 Others
  • 4.4 Market Size & Forecast by Application (2020-2035)
    • 4.4.1 Paediatrics
    • 4.4.2 Adults

5 Regional Analysis

  • 5.1 Global Market Overview
  • 5.2 North America Market Size (2020-2035)
    • 5.2.1 United States
      • 5.2.1.1 Vaccine Type
      • 5.2.1.2 Route of Administration
      • 5.2.1.3 Distribution Channel
      • 5.2.1.4 Application
    • 5.2.2 Canada
      • 5.2.2.1 Vaccine Type
      • 5.2.2.2 Route of Administration
      • 5.2.2.3 Distribution Channel
      • 5.2.2.4 Application
    • 5.2.3 Mexico
      • 5.2.3.1 Vaccine Type
      • 5.2.3.2 Route of Administration
      • 5.2.3.3 Distribution Channel
      • 5.2.3.4 Application
  • 5.3 Latin America Market Size (2020-2035)
    • 5.3.1 Brazil
      • 5.3.1.1 Vaccine Type
      • 5.3.1.2 Route of Administration
      • 5.3.1.3 Distribution Channel
      • 5.3.1.4 Application
    • 5.3.2 Argentina
      • 5.3.2.1 Vaccine Type
      • 5.3.2.2 Route of Administration
      • 5.3.2.3 Distribution Channel
      • 5.3.2.4 Application
    • 5.3.3 Rest of Latin America
      • 5.3.3.1 Vaccine Type
      • 5.3.3.2 Route of Administration
      • 5.3.3.3 Distribution Channel
      • 5.3.3.4 Application
  • 5.4 Asia-Pacific Market Size (2020-2035)
    • 5.4.1 China
      • 5.4.1.1 Vaccine Type
      • 5.4.1.2 Route of Administration
      • 5.4.1.3 Distribution Channel
      • 5.4.1.4 Application
    • 5.4.2 India
      • 5.4.2.1 Vaccine Type
      • 5.4.2.2 Route of Administration
      • 5.4.2.3 Distribution Channel
      • 5.4.2.4 Application
    • 5.4.3 Japan
      • 5.4.3.1 Vaccine Type
      • 5.4.3.2 Route of Administration
      • 5.4.3.3 Distribution Channel
      • 5.4.3.4 Application
    • 5.4.4 South Korea
      • 5.4.4.1 Vaccine Type
      • 5.4.4.2 Route of Administration
      • 5.4.4.3 Distribution Channel
      • 5.4.4.4 Application
    • 5.4.5 Rest of APAC
      • 5.4.5.1 Vaccine Type
      • 5.4.5.2 Route of Administration
      • 5.4.5.3 Distribution Channel
      • 5.4.5.4 Application
  • 5.5 Europe Market Size (2020-2035)
    • 5.5.1 Germany
      • 5.5.1.1 Vaccine Type
      • 5.5.1.2 Route of Administration
      • 5.5.1.3 Distribution Channel
      • 5.5.1.4 Application
    • 5.5.2 United Kingdom
      • 5.5.2.1 Vaccine Type
      • 5.5.2.2 Route of Administration
      • 5.5.2.3 Distribution Channel
      • 5.5.2.4 Application
    • 5.5.3 France
      • 5.5.3.1 Vaccine Type
      • 5.5.3.2 Route of Administration
      • 5.5.3.3 Distribution Channel
      • 5.5.3.4 Application
    • 5.5.4 Italy
      • 5.5.4.1 Vaccine Type
      • 5.5.4.2 Route of Administration
      • 5.5.4.3 Distribution Channel
      • 5.5.4.4 Application
    • 5.5.5 Spain
      • 5.5.5.1 Vaccine Type
      • 5.5.5.2 Route of Administration
      • 5.5.5.3 Distribution Channel
      • 5.5.5.4 Application
    • 5.5.6 Rest of Europe
      • 5.5.6.1 Vaccine Type
      • 5.5.6.2 Route of Administration
      • 5.5.6.3 Distribution Channel
      • 5.5.6.4 Application
  • 5.6 Middle East & Africa Market Size (2020-2035)
    • 5.6.1 Saudi Arabia
      • 5.6.1.1 Vaccine Type
      • 5.6.1.2 Route of Administration
      • 5.6.1.3 Distribution Channel
      • 5.6.1.4 Application
    • 5.6.2 United Arab Emirates
      • 5.6.2.1 Vaccine Type
      • 5.6.2.2 Route of Administration
      • 5.6.2.3 Distribution Channel
      • 5.6.2.4 Application
    • 5.6.3 South Africa
      • 5.6.3.1 Vaccine Type
      • 5.6.3.2 Route of Administration
      • 5.6.3.3 Distribution Channel
      • 5.6.3.4 Application
    • 5.6.4 Rest of MEA
      • 5.6.4.1 Vaccine Type
      • 5.6.4.2 Route of Administration
      • 5.6.4.3 Distribution Channel
      • 5.6.4.4 Application

6 Market Strategy

  • 6.1 Demand-Supply Gap Analysis
  • 6.2 Trade & Logistics Constraints
  • 6.3 Price-Cost-Margin Trends
  • 6.4 Market Penetration
  • 6.5 Consumer Analysis
  • 6.6 Regulatory Snapshot

7 Competitive Intelligence

  • 7.1 Market Positioning
  • 7.2 Market Share
  • 7.3 Competition Benchmarking
  • 7.4 Top Company Strategies

8 Company Profiles

  • 8.1 Sanofi S.A.
    • 8.1.1 Overview
    • 8.1.2 Product Summary
    • 8.1.3 Financial Performance
    • 8.1.4 SWOT Analysis
  • 8.2 GSK plc
    • 8.2.1 Overview
    • 8.2.2 Product Summary
    • 8.2.3 Financial Performance
    • 8.2.4 SWOT Analysis
  • 8.3 Sinovac Biotech Ltd
    • 8.3.1 Overview
    • 8.3.2 Product Summary
    • 8.3.3 Financial Performance
    • 8.3.4 SWOT Analysis
  • 8.4 Serum Institute of India Pvt. Ltd
    • 8.4.1 Overview
    • 8.4.2 Product Summary
    • 8.4.3 Financial Performance
    • 8.4.4 SWOT Analysis
  • 8.5 Zydus Group
    • 8.5.1 Overview
    • 8.5.2 Product Summary
    • 8.5.3 Financial Performance
    • 8.5.4 SWOT Analysis
  • 8.6 Takeda Pharmaceutical Company Limited
    • 8.6.1 Overview
    • 8.6.2 Product Summary
    • 8.6.3 Financial Performance
    • 8.6.4 SWOT Analysis
  • 8.7 Biological E Limited
    • 8.7.1 Overview
    • 8.7.2 Product Summary
    • 8.7.3 Financial Performance
    • 8.7.4 SWOT Analysis
  • 8.8 Shanghai Institute of Biological Products Co., Ltd
    • 8.8.1 Overview
    • 8.8.2 Product Summary
    • 8.8.3 Financial Performance
    • 8.8.4 SWOT Analysis
  • 8.9 Daiichi Sankyo Co., Ltd.
    • 8.9.1 Overview
    • 8.9.2 Product Summary
    • 8.9.3 Financial Performance
    • 8.9.4 SWOT Analysis
  • 8.10 Merck & Co., Inc.
    • 8.10.1 Overview
    • 8.10.2 Product Summary
    • 8.10.3 Financial Performance
    • 8.10.4 SWOT Analysis

9 About Us

  • 9.1 About Us
  • 9.2 Research Methodology
  • 9.3 Research Workflow
  • 9.4 Consulting Services
  • 9.5 Our Clients
  • 9.6 Client Testimonials
  • 9.7 Contact Us